PTC Therapeutics

Censa Pharmaceuticals Inc. is a pharmaceutical company based in Wellesley, Massachusetts, established in 2015. The company specializes in the development and commercialization of therapeutics aimed at treating ultra-orphan central nervous system (CNS) disorders, particularly those related to neurotransmitter degradation and synthesis. Censa's pipeline includes innovative solutions for extremely rare metabolic diseases that affect the CNS, with a focus on enabling patients to recover from debilitating conditions. As of May 2020, Censa operates as a subsidiary of PTC Therapeutics, Inc.

ClearPoint Neuro is a medical device company specializing in platforms for minimally invasive surgical procedures in the brain and heart under direct magnetic resonance imaging (MRI) guidance. Its flagship product, the ClearPoint system, enables precise insertion of catheters, electrodes, and laser fibers for treating neurological conditions and performing biopsies.

BioElectron Technology is a clinical-stage biotechnology company focused on developing innovative redox drugs aimed at advancing human health and addressing diseases. The company's proprietary drugs are designed to detect defects in mitochondrial proteins, which play a crucial role in cellular energy production and overall health. By targeting these defects, BioElectron Technology aims to provide new treatment options for mitochondrial diseases, which are often genetic disorders that can lead to severe health complications. Through its research and development efforts, the company seeks to offer novel solutions that could significantly improve patient outcomes in the realm of mitochondrial-related conditions.

Agilis Biotherapeutics, LLC is a biotechnology company focused on developing DNA therapeutics for patients with rare central nervous system diseases caused by single-gene defects. The company employs innovative technology to precisely target and restore lost gene function while minimizing off-target effects. Agilis Biotherapeutics specializes in treatments for conditions such as Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency, which leads to severe motor control issues and feeding difficulties, as well as Friedreich's Ataxia, a life-threatening neurodegenerative disease resulting from a defect in the FXN gene. Additionally, the company addresses Angelman Syndrome, a rare neurological disorder characterized by significant developmental delays. Founded in 2013 and based in Cambridge, Massachusetts, Agilis Biotherapeutics operates as a subsidiary of PTC Therapeutics, Inc. and has established a strategic partnership with Intrexon Corporation to enhance its therapeutic development efforts.